Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Biotest AG currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These cases are assigned to 3 distinct examiners across 3 distinct art units. This arrangement ensures that each of the 3 pending office actions is subject to an independent technical review. Such a spread indicates that the company's research and development efforts touch upon several different regulatory or technical niches.
GOTFREDSON, GAREN serves as the busiest examiner, currently overseeing 1 busiest examiner pending case. With the 3 pending office actions and 3 distinct examiners, the company's prosecution risk is decentralized across the Biotechnology & Pharmaceuticals sector. This structure requires a strategy that can adapt to the varied requirements of the 3 distinct art units. Because the workload is divided, the 1 busiest examiner pending case under GOTFREDSON, GAREN does not represent the entirety of the portfolio's active matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GOTFREDSON, GAREN | 1 | 40.0% | +28.0% |
| EVANS, CHRISTOPHER RYAN | 1 | 60.9% | +64.3% |
| TSAY, MARSHA M | 1 | 45.7% | +52.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17782684 | Method for Manufacturing a Fibrinogen Preparation | TSAY, MARSHA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18681561 | FIBRINOGEN COMPOSITIONS AND METHODS OF PREPARATION | GOTFREDSON, GAREN | — |
| 18249806 | METHOD AND KIT FOR TESTING IMMUNOMODULATORY POTENCY OF IMMUNOGLOBULIN COMPOSITIONS, e.g. FOR TREATMENT OF COVID 19 | EVANS, CHRISTOPHER RYAN | — |
| 17782684 | Method for Manufacturing a Fibrinogen Preparation | TSAY, MARSHA M | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| 1677 | 1 |
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18681561 | FIBRINOGEN COMPOSITIONS AND METHODS OF PREPARATION | GOTFREDSON, GAREN | 1619 | §103 | Non-Final OA | — | Pending | Feb 06, 2024 |
| 18249806 | METHOD AND KIT FOR TESTING IMMUNOMODULATORY POTENCY OF IMMUNOGLOBULIN COMPOSITIONS, e.g. FOR TREATMENT OF COVID 19 | EVANS, CHRISTOPHER RYAN | 1677 | §103 | Final Rejection | — | Pending | Apr 20, 2023 |
| 17782684 | Method for Manufacturing a Fibrinogen Preparation | TSAY, MARSHA M | 1656 | §101§103 | Final Rejection | — | Pending | Jun 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial